TP53 and head and neck squamous cell carcinoma: An ongoing clinical trial, EA3132, is investigating this topic by randomizing resected HNSCC without ENE or positive margins to radiation therapy versus chemoradiation therapy, and stratifying analysis based on TP53 mutation type (disruptive, non‐disruptive, and WT).26